Status:

TERMINATED

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Lead Sponsor:

Sanofi

Conditions:

Liver Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment. The secondary objectives of the study are: *...

Detailed Description

AVE1642 will be administered as an IV infusion on day 1 and then every 3 weeks for at least 2 infusions for evaluability requirements. Curative and / or prophylactic management of allergic reactions d...

Eligibility Criteria

Inclusion

  • Patients not eligible for surgical resection, liver transplantation, local ablation techniques or chemoembolisation and with histologically proven liver carcinoma whenever possible or combination of radiologically documented hypervascular liver tumour and α foeto protein level ≥ 400 ng/ml
  • Signed and dated approved patient informed consent form prior to enrollment into the study

Exclusion

  • ECOG performance status \> 2
  • Inadequate organ function:
  • Neutrophils (ANC) \< 1,500/mm3
  • Hemoglobin \< 10g/dl
  • Platelets \< 100,000/mm3
  • Total bilirubin \> 1.5 x ULN
  • ASAT, ALAT \> 3 x ULN
  • Creatininemia \> 1.5 x ULN (or ≥ 2.0 mg/dl)
  • INR \> 1.6
  • Liver cirrhosis Child Pugh B or C (score \> 6)
  • HbA1C \> 8%
  • No measurable or evaluable tumoral lesion
  • Patients not eligible for sorafenib therapy and for whom this therapy cannot be postponed by 3 weeks (during AVE1642 single treatment period) in dose escalation part
  • Prior exposure to an anti-IGF-1R class compound
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2009

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00791544

Start Date

November 1 2008

End Date

November 1 2009

Last Update

August 4 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sanofi-Aventis Administrative Office

Paris, France